COMMUNIQUÉS West-GlobeNewswire

LSL Pharma Group Secures $3.8 Million as the Second and Final Tranche of Its Private Placement of Units
24/04/2024
BOUCHERVILLE, Quebec, April 24, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC . (TSXV: LSL) (the " Corporation " or " LSL Pharma "), a Canadian integrated pharmaceutical company, today announced the second and final [...]
Augmedix Launches Industry’s First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments
24/04/2024
Following incubation with HCA Healthcare EDs, Augmedix announces the general availability of Augmedix Go in emergency departments SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in [...]
Sharecare to report first quarter fiscal 2024 financial results on Thursday, May 9
24/04/2024
ATLANTA, April 24, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR ), the digital health company that helps people manage all their health in one place, today announced that it will report first quarter fiscal 2024 [...]
Good Supply Cannabis Introduces New Signature ‘Bud Squad’ Products
24/04/2024
TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company today announced the release of new cannabis flower [...]
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
24/04/2024
TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with [...]
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
24/04/2024
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the [...]
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
24/04/2024
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster [...]
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
24/04/2024
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi ® and Simponi Aria ® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritis Alvotech [...]
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
24/04/2024
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria ® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritis Alvotech [...]
Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
24/04/2024
Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next [...]
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
24/04/2024
MILAN, Italy, April 24, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for [...]
Pharming Group to report first quarter 2024 financial results on May 8
24/04/2024
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period [...]
Vistin Pharma ASA: First quarter 2024 financial results
24/04/2024
Oslo, Norway, 24 th of April 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024. Revenue in the first quarter ended at MNOK 104 compared to MNOK 101 in Q1 2023. Sales [...]
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent
24/04/2024
Press Release Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent April 24, 2024 – release at 07:30 CET Sophia Antipolis, France Nicox SA ( [...]
Nicox : Deuxième convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 6 mai 2024 et désignation d’un mandataire ad hoc
24/04/2024
Communiqué de presse Nicox : Deuxième convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 6 mai 2024 et désignation d’un mandataire ad hoc 24 avril 2024 – diffusion à 07h30 Sophia Antipolis, France Nicox [...]
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
24/04/2024
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, [...]
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
24/04/2024
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.     Q1 2024   Q1 2023   % change   €m   €m   [...]
Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024
24/04/2024
PARIS, FRANCE, 24 avril 2024 - Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de spécialité, publie aujourd’hui son chiffre d’affaires pour le premier trimestre 2024. Q1 2024 Q1 2023 % change €m [...]
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023
24/04/2024
PRESS RELEASE - PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of [...]

Pages